Filing Flows › RenovoRx (RNXT) › Recalls, complaints & regulation
RenovoRx (RNXT): clinical trials
RenovoRx (RNXT) beyond its filings: 2 active clinical trials.
RenovoRx's latest quarter
RenovoRx, Q3 2026: revenue $1.1M (+301% year over year), operating margin -303.6%, net loss $3.6M, operating cash flow −$2.5M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does RenovoRx have?
2 active studies on ClinicalTrials.gov, 1 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.